Eli Lilly and Company and Purdue University are keeping their partnership alive beyond it’s previously expected years. In an ...

Amazon.com, Nvidia, Tesla, and the rest of the Magnificent Seven stocks jump as the U.S. and China reach an agreement to ...

Now, this won't come as too much of a surprise to Eli Lilly and its peers. A few weeks ago, the company's CEO, David Ricks, ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Eli Lilly and Company (NYSE: LLY) and Purdue University announced today a significant expansion of their long-standing alliance, with Lilly's planned investment of up to $250 million in the ...

In addition to eliciting greater weight loss than Novo Nordisk’s Wegovy, Eli Lilly’s Zepbound does not come at the expense of ...

The investment over the next eight years could be the largest ever industry-academic agreement of its kind in the U.S., the ...

Eli Lilly (NYSE:LLY) recently announced leadership transitions, including new roles for Ilya Yuffa, Patrik Jonsson, and ...

Eli Lilly and Purdue University expand their partnership with a $250 million investment to advance pharmaceutical innovation ...

Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of ...

Growth stocks often don't come cheap, especially when their prospects look great, as is the case with Eli Lilly ( LLY 1.09%).

Eli Lilly said sales of weight loss drug Zepbound and diabetes treatment Mounjaro surged in the first quarter.